Liaocheng Third People's Hospital Trials

Liaocheng Third People's Hospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yang, Lei

Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

Recruiting

165

RoW

rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention

The First Affiliated Hospital of Dalian Medical University, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Anqing Municipal Hospital, Henan Cancer Hospital, Wuhan Union Hospital, China, Peking University Shougang Hospital, Chinese PLA General Hospital, Liaoning Tumor Hospital & Institute, Tianjin Medical University Cancer Institute and Hospital, Henan Provincial People's Hospital, Shanxi Provincial Cancer Hospital, Beijing Sanhuan Cancer Hospital, Hebei Medical University Fourth Hospital, Tongji Hospital, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Bethune Charitable Foundation

Cancer Treatment Induced Thrombocytopenia

06/24

08/24

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（）

Recruiting

2105

RoW

14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management

Capital Medical University

Acute Ischemic Stroke, Anterior Circulation Brain Infarction

11/26

02/27

NCT05438875: The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

Recruiting

RoW

all-trans retinoic acid, retinoic acid, Eltrombopag, TPO-RA

Peking University People's Hospital, Beijing Friendship Hospital, Beijing Tongren Hospital, Beijing Hospital, Navy General Hospital, Beijing

Purpura, Thrombocytopenic, Idiopathic

12/24

03/25

NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting

350

RoW

YK-209A tablet, Pemetrexed+carboplatin/Cisplatin

Suzhou Puhe Pharmaceutical Technology Co., LTD

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

07/25

12/26

TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Recruiting

518

RoW

TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-small Cell Lung Cancer

08/25

12/25

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recruiting

100

RoW

Toripalimab, Tuoyi

Shanghai Junshi Bioscience Co., Ltd.

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

12/22

03/23

NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Recruiting

200

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Advanced Solid Tumor

12/23

06/24

NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Recruiting

261

RoW

Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005）

Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH

Ankylosing Spondylitis

02/25

10/25

NCT06538844: Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy

Completed

134

RoW

Intravenous infusion of human albumin, Saline

Capital Medical University, Xuanwu Hospital, Beijing

Acute Ischemic Stroke

12/24

03/25

JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC

Recruiting

1/2

725

RoW

JSKN003

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Solid Tumor

12/24

12/26

NCT05677581: Longitudinal Study on the Influence of Iodine Nutrition Status on Thyroid Function of Childbearing Age Women During Pregnancy and 6 Weeks Postpartum

Recruiting

N/A

2100

RoW

iodine nutrition status

Beijing Friendship Hospital

Thyroid Function, Iodine Nutrition Status

12/24

NCT06795737: ExCR's Effects and Safety in Vulnerable ADHF Patients

Not yet recruiting

N/A

RoW

Exercise rehabilitation, Conventional rehabilitation

YE Jing

Acute Decompensated Heart Failure (ADHF)

02/26

06/26

SSILA, NCT07023575: Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions

Not yet recruiting

N/A

100000

RoW

China-Japan Friendship Hospital

Interstitial Lung Abnormalities

11/28

Chang, Liguo

SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting

1380

RoW

Shuxuening Injection, Placebo

Beijing Tiantan Hospital

Ischemic Stroke, Acute

06/25

12/26

TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting

1380

RoW

Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin

Beijing Tiantan Hospital

Ischemic Stroke, Acute

12/25

12/26

CHANCE-3, NCT05439356: Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack

Completed

8343

RoW

Colchicine, Placebo colchicine

Beijing Tiantan Hospital

Ischemic Stroke, TIA

07/23

04/24

NCT06319846: Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）

Recruiting

4674

RoW

Tirofiban, Placebo

Beijing Tiantan Hospital

Ischemic Stroke, Acute, TIA, Symptomatic Intracranial Artery Stenosis

10/25

12/26

Chi, Haitao

SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting

1380

RoW

Shuxuening Injection, Placebo

Beijing Tiantan Hospital

Ischemic Stroke, Acute

06/25

12/26

TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting

1380

RoW

Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin

Beijing Tiantan Hospital

Ischemic Stroke, Acute

12/25

12/26

Fan, Yan

RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（）

Recruiting

2105

RoW

14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management

Capital Medical University

Acute Ischemic Stroke, Anterior Circulation Brain Infarction

11/26

02/27

NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting

110

RoW

68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET

Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.

Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma

12/25

07/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Yang, Lei

Circular, NCT05411705: Efficacy and Safety of rhTPO's Prophylactic Treatment of CTIT in Patients With High Risk of Cardiac Injury

Recruiting

165

RoW

rhTPO, Recombinant human thrombopoietin, TPIAO, Control, No intervention

Cancer Treatment Induced Thrombocytopenia

06/24

08/24

NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting

560

RoW

Irinotecan Hydrochloride Injection, HX008, Placebo

Taizhou Hanzhong biomedical co. LTD

Stomach Cancer

08/23

RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（）

Recruiting

2105

RoW

14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management

Capital Medical University

Acute Ischemic Stroke, Anterior Circulation Brain Infarction

11/26

02/27

NCT05438875: The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

Recruiting

RoW

all-trans retinoic acid, retinoic acid, Eltrombopag, TPO-RA

Peking University People's Hospital, Beijing Friendship Hospital, Beijing Tongren Hospital, Beijing Hospital, Navy General Hospital, Beijing

Purpura, Thrombocytopenic, Idiopathic

12/24

03/25

NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting

350

RoW

YK-209A tablet, Pemetrexed+carboplatin/Cisplatin

Suzhou Puhe Pharmaceutical Technology Co., LTD

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

07/25

12/26

Recruiting

518

RoW

TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Non-small Cell Lung Cancer

08/25

12/25

NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Active, not recruiting

878

RoW

JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy

Shanghai Junshi Bioscience Co., Ltd.

Gastric or Esophagogastric Junction Adenocarcinoma

06/26

07/28

Recruiting

100

RoW

Toripalimab, Tuoyi

Shanghai Junshi Bioscience Co., Ltd.

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

12/22

03/23

NCT05372120: A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

Recruiting

200

RoW

ICP-192

Beijing InnoCare Pharma Tech Co., Ltd.

Advanced Solid Tumor

12/23

06/24

NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

Recruiting

261

RoW

Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005）

Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH

Ankylosing Spondylitis

02/25

10/25

NCT06538844: Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy

Completed

134

RoW

Intravenous infusion of human albumin, Saline

Capital Medical University, Xuanwu Hospital, Beijing

Acute Ischemic Stroke

12/24

03/25

JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC

Recruiting

1/2

725

RoW

JSKN003

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Advanced Solid Tumor

12/24

12/26

NCT05677581: Longitudinal Study on the Influence of Iodine Nutrition Status on Thyroid Function of Childbearing Age Women During Pregnancy and 6 Weeks Postpartum

Recruiting

N/A

2100

RoW

iodine nutrition status

Beijing Friendship Hospital

Thyroid Function, Iodine Nutrition Status

12/24

NCT06795737: ExCR's Effects and Safety in Vulnerable ADHF Patients

Not yet recruiting

N/A

RoW

Exercise rehabilitation, Conventional rehabilitation

YE Jing

Acute Decompensated Heart Failure (ADHF)

02/26

06/26

SSILA, NCT07023575: Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions

Not yet recruiting

N/A

100000

RoW

China-Japan Friendship Hospital

Interstitial Lung Abnormalities

11/28

Chang, Liguo

SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting

1380

RoW

Shuxuening Injection, Placebo

Beijing Tiantan Hospital

Ischemic Stroke, Acute

06/25

12/26

TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting

1380

RoW

Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin

Beijing Tiantan Hospital

Ischemic Stroke, Acute

12/25

12/26

CHANCE-3, NCT05439356: Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack

Completed

8343

RoW

Colchicine, Placebo colchicine

Beijing Tiantan Hospital

Ischemic Stroke, TIA

07/23

04/24

NCT06319846: Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events(CHANCE-4）

Recruiting

4674

RoW

Tirofiban, Placebo

Beijing Tiantan Hospital

Ischemic Stroke, Acute, TIA, Symptomatic Intracranial Artery Stenosis

10/25

12/26

Chi, Haitao

SHINY, NCT06157502: Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke

Recruiting

1380

RoW

Shuxuening Injection, Placebo

Beijing Tiantan Hospital

Ischemic Stroke, Acute

06/25

12/26

TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Recruiting

1380

RoW

Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin

Beijing Tiantan Hospital

Ischemic Stroke, Acute

12/25

12/26

Fan, Yan

RECAST-MT, NCT06559241: Remote Ischemic Conditioning for Acute Ischemic Stroke Treated with Mechanical Thrombectomy（）

Recruiting

2105

RoW

14-day remote ischemic conditioning, 14-day RIC, 30-day remote ischemic conditioning, 30-day RIC, Endovascular thrombectomy, EVT, Best medical management

Capital Medical University

Acute Ischemic Stroke, Anterior Circulation Brain Infarction

11/26

02/27

NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Recruiting

110

RoW

68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET

Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd.

Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma

12/25

07/26



	Diseases Companies Products Productz Mechanisms of Action Sites